Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy of Oral Belumosudil in Black or African American, American Indian or Alaska Native, and Native Hawaiian or Other Pacific Islander Male and Female Participants Aged 12 Years and Above With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy
NCT05567406 · Kadmon, a Sanofi Company · PHASE2 · withdrawn · last registry update 2026-02-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision.” | – | Registry record, Kadmon, a Sanofi Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ROCK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-16Also stopped (suspended): Northside Hospital, Inc., Belumosudil + Rituximab (NCT06046248)
- 2026-08-18Phase 3 first posted: Sanofi, Belumosudil (NCT07771439)
- 2026-08-06Results posted on the registry: Kowa Research Institute, Inc., Ripasudil + Placebo (NCT05528172)
- 2026-01-02Results posted on the registry: Laboratoires Thea, T4090 0.2% + T4090 0.3% (NCT06394973)
- 2025-07-24Phase 3 first posted: Alcon Research, Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution + Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NCT07082816)
- 2025-05-07Phase 3 first posted: University Hospital Dubrava, Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution + Placebo (NCT06960629)
- 2025-05-02Results posted on the registry: Kadmon, a Sanofi Company, Belumosudil 200 mg QD + Belumosudil 200 mg BID (NCT05305989)
- 2025-03-06Phase 3 first posted: baotai Liang, Fasudil hydrochloride and PD1 inhibitor combined with androgen deprivation therapy + Placebo combined with androgen deprivation therapy (NCT06861192)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision